Navigation Links
Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
Date:8/28/2009

approval."

Outline of the EXAMINE Trial

    Title:             A Multicenter, Randomized, Double-Blind, Placebo-
                       Controlled Study to Evaluate Cardiovascular Outcomes
                       Following Treatment with Alogliptin in Addition to
                       Standard of Care in Subjects with Type 2 Diabetes and
                       Acute Coronary Syndrome

    Study Start:       September 2009

    Study Completion:  December 2014

    No. of Patients:   Approximately 5,400

    Primary Outcome:   Time from randomization to the occurrence of the
                       Primary Major Adverse Cardiac Events defined as
                       a composite of cardiovascular death, nonfatal
                       myocardial infarction and nonfatal stroke

    Secondary Outcome: Time from randomization to the occurrence of the
                       Secondary Major Adverse Cardiac Events defined
                       as a composite of cardiovascular death, nonfatal
                       myocardial infarction, nonfatal stroke and urgent
                       revascularization due to unstable angina

    Study Sites:       Approximately 1,000 sites in the U.S., Europe, Asia

About Takeda Pharmaceutical Company Limited

Located in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to striving toward better health for individuals and progress in medicine by developing superior pharmaceutical products. Additional information about Takeda is available through its corporate Web site, www.takeda.com.

About Takeda Pharmaceuticals North America, Inc. and Takeda Globa
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
11. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... , Dec. 22, 2014  ConvaTec, a privately-held ... Moraviec has been appointed Interim Chief Executive Officer of ... Moraviec succeeds Ken Berger .  "The Board of ... in leading ConvaTec over the past three years," said ... of Directors.  "We are confident that the company is ...
(Date:12/22/2014)...  Mark Farrah Associates (MFA), www.markfarrah.com , ... the 2015 marketplace exchange projections and insights about ... According to a recent ASPE (Office of the ... Health and Human Services) report, an estimated 6.7 ... through the Marketplace as of October 2014 and ...
(Date:12/22/2014)... TAIPEI , Dec. 22, 2014 ... received Notice of Allowance for AC-201, TWi Biotechnology,s ... Office in China for ... or its pharmaceutically acceptable salts, active metabolite for ... covers the methods of treatment using AC-201 for ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Insights into the Marketplace and Individual Market Growth 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... JOSE, Calif., Sept. 26, 2011 SI-BONE, Inc. (San ... the use of a minimally invasive surgical (MIS) device ... it has closed $16.0 million in financing for expansion ... Equity Partners, of Menlo Park, California, led the round ...
... today announced TIGR® Matrix Surgical Mesh , the world,s first ... mesh. First introduced in the US in 2010, TIGR® Matrix ... as an alternative to permanent synthetic mesh and expensive biologic devices. ... Surgical Mesh TIGR® Matrix Surgical ...
Cached Medicine Technology:SI-BONE, Inc. Closes $16.0 Million Financing Led by Montreux Equity Partners 2SI-BONE, Inc. Closes $16.0 Million Financing Led by Montreux Equity Partners 3Novus Scientific Announces the World's 1st Long-Term Absorbable Mesh as an Alternative to Non-Absorbable Synthetic Mesh 2
(Date:12/22/2014)... Coral Gables is preparing to welcome the premier ... its new clinic location set to open in 2015. The ... of dealing with this common childhood parasite by offering full ... clinic locations in South Florida, or in the comfort of ... expand developed naturally out of the demand for the high-level ...
(Date:12/22/2014)... 22, 2014 International efforts ... virus epidemic are receiving further support from ... nongovernmental organizations (NGOs) and other charitable organizations. ... workers, emergency responders, patients and others can ... the CmTP MediDefense system , which ...
(Date:12/22/2014)... December 22, 2014 Super Saturday, the ... this year as the busiest day in the 2014 ... The Grass Station had a steady pre-Christmas stream of ... this past Saturday. , “I definitely intend to take ... a Denver resident who was enjoying The Grass Station’s ...
(Date:12/22/2014)... The MedTech industry is gearing up for new growth and ... AB of Sweden, is prepared to facilitate the manufacturing expansion ... All signs point to growth in the MedTech industry with ... of the excise tax originally levied to fund the ... of 9.3% and PartnerTech Inc. is prepared to answer the ...
(Date:12/22/2014)... Luxury Linen purveyor Peacock Alley ... to provide logistics and support for one of Dallas’ ... a long history of giving back to the community in ... year's Toy Drive were Whataburger® and 99.5 The Wolf. , ... holidays. Providing gifts to children who would otherwise not receive ...
Breaking Medicine News(10 mins):Health News:Professional In-Home All-Natural Lice Removal Service Expands to Coral Gables and surrounding areas. 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Customers at Colorado’s Grass Station Say They’re Enjoying the Experience of Legally Purchasing Marijuana this Year to Give as Christmas Presents to Friends and Family 2Health News:PartnerTech Inc. Poised for Growth in MedTech 2Health News:Peacock Alley and Community Partners of Dallas Fulfill an Estimated 12,000 Holiday Wishes for Deserving Children 2
... food to infants less than six months old is not ... allergies later and new moms should rather breastfeed them exclusively, ... avoided for the first six months, and certain items like ... until even later, according to the American College of Allergy, ...
... Consuming naturally occurring compounds in cocoa could improve ... also help blood flow// in menopausal women with ... and gives us new insights into how cocoa ... ways not previously known,' said Harold Schmitz, PhD, ...
... embryo formation has been discovered in malignant melanoma cells ... Scientist discovered this protein called Nodal by injecting malignant ... were able to induce abnormal embryonic skull and backbone ... published in online issue of the journal, Nature Medicine. ...
... the researchers at the University of Florida, Gainesville, mice based ... treat hereditary diseases of the heart.// , This ... with muscular dystrophy that damages the heart. The findings, published ... the way for studies in humans that could begin as ...
... Health service helpline NHS 24 has been criticized severely because a ... old lady.// ,Retired nurse Mary Smith, 87 had an ... helpline twice but the nurse curtly replied that she could not ... for a GP to attend to her. Then when the GP ...
... Hyderabad-based Aurobindo Pharma Ltd today said it has ... fixed drug combination product used for anti-HIV treatment. ... contains Lamivudine 150mg+2idovudine300mg tablets co-packaged with Abacavir 300mg ... ,This combination pack enhances convenience, is cost-effective ...
Cached Medicine News:Health News:Protein Involved In Embryo Formation Found In Malignant Cells 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 2Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 3Health News:Gene Therapy Technique for Inherited Heart Problems in The Pipeline 4
Stainless steel threaded Steinman Pins available in point types A,D, E, and F....
Round Bevel-Point Pin Sets available in 2.3mm, 3.1mm, 4.7mm, and 6.3mm sizes....
Knowles Pins are available in 9" (228mm) overall length with 9/64" (3.5mm) shaft diameter and 1/4" (6.4mm) square bead....
... Unite Device is the anterior alternative to the ... device features the same 70% fenestrations as Ray ... is paramount in the formation of new bone. ... system promotes load sharing between the device and ...
Medicine Products: